Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line-Reference-Cited by-同舟云学术

Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line

Published:2020-03-09 Issue:6 Volume:111 Page:812-825
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Sakurai Masatoshi, ,Okamoto Shinichiro,Matsumura Itaru,Murakami Satsuki,Takizawa Makiko,Waki Masato,Hirano Daiki,Watanabe-Nakaseko Reiko,Kobayashi Naoki,Iino Masaki,Mitsui Hideki,Ishikawa Yuichi,Takahashi Naoto,Kawaguchi Tatsuya,Suzuki Ritsuro,Yamamoto Kazuhito,Kizaki Masahiro,Ohnishi Kazunori,Naoe Tomoki,Akashi Koichi

Funder

Novartis Pharmaceuticals

Bristol-Myers Squibb

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-020-02843-8.pdf

Reference30 articles.

1. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

2. Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res. 2009;15:7519–27.